Analysts’ recommendations and target price

Wall Street analysts expect a potential upside of 2.45% for United Therapeutics (UTHR) based on the stock’s closing price on March 21.

Analysts revised the company’s target price upward from $125.27 in January and February to $126.00 in March. The current consensus analyst recommendation for the stock is a “hold.”

Analysts Have Mixed Opinions on United Therapeutics This Month

Of the 12 analysts covering United Therapeutics, two have given it “strong buys,” five have given it “holds,” four have given it “sells,” and one has given it a “strong sell.” The highest target price estimate for the company is $269, and the lowest is $95.

On March 21, United Therapeutics closed at $122.99, 1.44% higher than its previous closing price, 22.92% higher than its 52-week low of $100.06, and 5.39% lower than its 52-week high of $130.00. The company’s market cap is $5.34 billion.

Based on its closing price on March 21, United Therapeutics has reported returns of 5.09% in the last week, 4.33% in the last month, and 15.92% in the last quarter. The company has reported returns of -2.54% in the last half year, 14.19% in the last year, and 12.94% year-to-date.

Revenue estimates

In its fourth quarter, United Therapeutics reported revenue of $381.40 million, a YoY (year-over-year) fall of 17.93% but $25.59 million higher than the consensus estimate. The company reported non-GAAP (generally accepted accounting principles) EPS of $3.34, a YoY fall of 14.14% but still $0.79 higher than the consensus estimate. According to the company’s fourth-quarter earnings conference call, the loss of patent protection for Adcirca negatively affected its 2018 revenue performance.

Analysts expect United Therapeutics’ revenue to see YoY falls of -14.22% to $333.86 million in the first quarter, -26.90% to $324.92 million in the second quarter, -26.42% to $303.68 million in the third quarter, and -19.78% to $305.97 million in the fourth quarter of 2019. They expect United Therapeutics’ revenue to see YoY falls of -20.89% to $1.29 billion in 2019, -7.82% to $1.19 billion in 2020, and -3.17% to $1.15 billion in 2021.

Next, we’ll discuss analysts’ recommendations and projections for Jazz Pharmaceutical.

Latest articles

PG&E (PCG) shares are trading more than 25% lower on Monday. A federal judge ruled that the utility must face victims of the Tubbs Fire.

Last week (ended August 16) was rough for Canopy Growth (WEED)(CGC) stock. It fell about 14% after the company's fiscal 2020 first-quarter earnings report.

Apple shares rose close to 3% in early hour trading on Monday. So, why is Apple stock trading higher? The market sentiment might have turned positive.

Huawei plans to launch its own mapping service as soon as this October. But Huawei’s Map Kit will initially not be a consumer mapping service.

Ford stock fell 5.2% last week. The fall extended the stock’s decline to 13.3% since its second-quarter results on July 24.

In April, Amazon announced its plan to transform its free two-day shipping program to a free one-day shipping program for its Prime customers.